Hand and Wrist / Carpal Tunnel Syndrome (CTS) / PRP / VAS + QuickDASH

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP treatments tailored for Carpal Tunnel Syndrome (CTS).

The Platelet Rich Plasma “PRP” Market is valued at 828.8 Billion in 2023 and is estimated to grow to over 3 Trillion by 2032.  Carpal Tunnel Syndrome is considered the most common entrapment neuropathy, accounting for 90% of entrapment neuropathy cases globally.  With modern jobs increasingly involving computer use and repetitive tasks, some reports suggest a rising prevalence of carpal tunnel syndrome.  As demand to treat CTS increases, manufacturers will seek real-world safety and efficacy data to enhance product development and regulatory approvals.

This Circle helps physicians obtain and aggregate high-quality real-world data from PRP treatments that companies are actively seeking.  Participation is minimally burdensome, and members will receive recurring license fees based on their contribution of treatment cases, outcomes, and other relevant data.